Net sales rose 16% year-over-year to 61.2 MSEK, with improved Q4 results due to cost reductions, but full-year losses deepened. Strong demand in PFAS decontamination and healthcare, plus a planned 60 MSEK rights issue, support growth prospects.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.